Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue

Trends in Immunology

Volumn 23, Issue 12, 2002, Pages 586-591

  Van Baarle, Debbie ^a   Kostense, Stefan ^a   Van Oers, Marinus H J ^a   Hamann, Dorte ^a   Miedema, Frank ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD8 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CANCER RISK; CELL MATURATION; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; EFFECTOR CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NONHODGKIN LYMPHOMA; PERSISTENT VIRUS INFECTION; PHENOTYPE; REVIEW; VIRUS INFECTION;

ANTIGENS, CD27; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; EPSTEIN-BARR VIRUS INFECTIONS; HIV INFECTIONS; HUMANS; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES, CYTOTOXIC; VIRUS DISEASES;

EID: 0036900141     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)02326-8     Document Type: Review

References (53)

1. Wodarz D. The importance of lytic and nonlytic immune responses in viral infections. Trends Immunol. 23:2002;194-200.
2. Riera L., et al. Murine cytomegalovirus replication in salivary glands is controlled by both perforin and granzymes during acute infection. Eur. J. Immunol. 30:2000;1350-1355.
3. + T cells clear influenza virus by perforin or Fas-dependent processes. J. Immunol. 159:1997;5197-5200.
4. Guidotti L.G., et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 4:1996;25-36.
5. Altman J.D., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
6. Ogg G.S., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 279:1998;2103-2106.
7. Ogg G., et al. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific T lymphocytes: correlation with disease progression. J. Virol. 73:1999;9153-9160.
8. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187:1998;1395-1402.
9. Jin X., et al. High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections. J. Infect. Dis. 181:2000;165-175.
10. + T-cell expansions: evidence for impaired T-cell effector function. Eur. J. Immunol. 31:2001;677-686.
11. Rinaldo C.R., et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J. Virol. 69:1995;5838-5842.
12. Pontesilli O., et al. Longitudinal analysis of human immunodeficiency virus type-1 specific cytotoxic T-lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J. Infect. Dis. 178:1998;1008-1018.
13. Klein M.R., et al. Kinetics of Gag-specific CTL responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181:1995;1365-1372.
14. Kersten M.J., et al. EBV-specific cytotoxic T-cell responses in HIV-1 infection: different kinetics in patients progressiong to opportunistic infection or non-Hodgkin's lymphoma. J. Clin. Invest. 99:1997;1525-1533.
15. + HIV-specific T cells during progression to AIDS. Blood. 99:2002;2505-2511.
16. + T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin's lymphoma. Blood. 98:2001;146-155.
17. Dunbar P.R., et al. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J. Immunol. 165:2000;6644-6652.
18. Valmori D., et al. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res. 61:2001;509-512.
19. Valmori D., et al. Analysis of the cytolytic T-lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376. Cancer Res. 59:1999;4050-4055.
20. Lee P.P., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:1999;677-685.
21. Klenerman P., et al. HIV: current opinion in escapology. Curr. Opin. Microbiol. 5:2002;408-415.
22. + T-cell development. Immunol. Today. 20:1999;177-180.
23. + T cells from a memory to memory/effector phenotype. J. Immunol. 168:2002;5538-5550.
24. + T-cell response. J. Immunol. 168:2002;5455-5464.
25. - cells are induced by antigen and evolve through extensive rounds of division. Int. Immunol. 11:1999;1027-1033.
26. + T cells. J. Exp. Med. 186:1997;1407-1418.
27. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8:2002;379-385.
28. + T-cell subsets during acute Epstein-Barr virus and human immunodeficiency virus infection in man. J. Infect. Dis. 182:2000;451-458.
29. Champagne P., et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 410:2001;106-111.
30. Dunne P.J., et al. Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood. 100:2002;933-940.
31. + T cells in healthy an immunosupressed virus carriers. Blood. 98:2001;754-761.
32. Gillespie G.M., et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J. Virol. 74:2000;8140-8150.
33. + T-cell memory: relationships beteween epitope specificity, cell phenotype and immediate effector function. J. Immunol. 167:2001;2019-2029.
34. + T cells is associated with progression to viral disease in HIV-infection. AIDS. 16:2002;2001-2011.
35. Appay V., et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192:2000;63-76.
36. Chen G., et al. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood. 98:2001;156-164.
37. Hintzen R., et al. Regulation of CD27 expression on subsets of mature T lymphocytes. J. Immunol. 151:1993;2426-2435.
38. van Baarle D., et al. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus Type 1 infection is not predicitve of AIDS-related non-Hodgkin lymphoma. J. Infect. Dis. 186:2002;405-409.
39. + cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J. Infect. Dis. 183:2001;197-205.
40. Ahmed R., Gray D. Immunological memory and protective immunity: understanding their relation. Science. 272:1996;54-60.
41. Lieberman J., et al. Avoiding the kiss of death: how HIV and other chronic viruses survive. Curr. Opin. Immunol. 14:2002;478-486.
42. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:1994;8056-8063.
43. + T-cell deficient mice. J. Virol. 68:1994;4700-4704.
44. von Herrath M.G., et al. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70:1996;1072-1079.
45. + T cells. J. Exp. Med. 184:1996;863-871.
46. Hasenkrug K.J., et al. Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice. J. Virol. 72:1998;6559-6564.
47. Rooney C.M., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 92:1998;1549-1555.
48. Brodie S.J., et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med. 5:1999;34-41.
49. Becker T.C., et al. Interleukin-15 is required for proliferative renewal of virus-specific memory CD8 T cells. J. Exp. Med. 195:2002;1541-1548.
50. Doherty P.C., Christensen J.P. Accessing complexity: the dynamics of virus-specific T-cell responses. Annu. Rev. Immunol. 18:2000;561-592.
51. + T cells. J. Immunol. 168:2002;4184-4191.
52. + T-cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med. 195:2002;893-905.
53. - T lymphocytes. antigenic and functional properties. J. Immunol. 4:1993;1147-1159.